Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would b...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Arjyal, Amit, Basnyat, Buddha, Nhan, Ho Thi, Koirala, Samir, Giri, Abhishek, Joshi, Niva, Shakya, Mila, Pathak, Kamal Raj, Mahat, Saruna Pathak, Prajapati, Shanti Pradhan, Adhikari, Nabin, Thapa, Rajkumar, Merson, Laura, Gajurel, Damodar, Lamsal, Kamal, Lamsal, Dinesh, Yadav, Bharat Kumar, Shah, Ganesh, Shrestha, Poojan, Dongol, Sabina, Karkey, Abhilasha, Thompson, Corinne N, Thieu, Nga Tran Vu, Thanh, Duy Pham, Baker, Stephen, Thwaites, Guy E, Wolbers, Marcel, Dolecek, Christiane
Médium: Technical Report
Jazyk:en_US
Vydáno: Lancet Infect Dis 2016 2016
Témata:
Gatifloxacin versus
Enteric Fever
Nepal
On-line přístup:http://103.69.126.140:8080/handle/123456789/818
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
Popis
Shrnutí:Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever.

Podobné jednotky